Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6% – Time to Sell?

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price was down 3.6% during mid-day trading on Tuesday . The company traded as low as $22.76 and last traded at $23.42. Approximately 64,977 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 223,010 shares. The stock had previously closed at $24.29.

Key Headlines Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Alto announced a roughly $120 million private placement (PIPE), providing significant near-term cash to advance its depression drug program and extending runway; this is a major liquidity positive for a clinical-stage biotech. Alto Neuroscience Announces $120 Million Private Placement Financing
• Positive Sentiment: Coverage in financial/health outlets highlighted the financing and linked it to upside in the stock as the company pushes its depression drug candidate forward. This media attention can support investor interest. Alto Neuroscience stock rises as firm secures $120M to advance depression drug
• Positive Sentiment: Alto beat Q4/ FY‑2025 consensus on EPS (reported ($0.45) vs. ($0.56) est.), a modest operational beat that supports the company’s progress narrative. Alto Neuroscience Q4 Results
• Neutral Sentiment: Company filed its full‑year 2025 results and business highlights; management framed 2026 as having a strong clinical/financial foundation — useful context but largely reiterative. Full Year 2025 Financial Results and Highlights
• Negative Sentiment: Wedbush raised its price target from $13 to $22 but maintained a “neutral” rating — the PT is still below current levels, signaling limited upside from that shop and potentially tempering momentum. Wedbush raises PT to $22, neutral rating
• Negative Sentiment: Some investors view the PIPE as dilutive despite its cash benefit; dilution concerns and issuance mechanics often pressure biotech shares near financing announcements. MSN coverage of the PIPE

Analyst Ratings Changes

ANRO has been the subject of a number of research analyst reports. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday. Wedbush lifted their price objective on shares of Alto Neuroscience from $13.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Finally, BTIG Research raised their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.17.

Alto Neuroscience Stock Performance

The company has a current ratio of 15.42, a quick ratio of 15.42 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $734.65 million, a PE ratio of -10.33 and a beta of 2.51. The business’s fifty day moving average is $17.96 and its two-hundred day moving average is $13.22.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. Equities research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vestal Point Capital LP increased its stake in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after purchasing an additional 1,535,000 shares in the last quarter. Commodore Capital LP purchased a new position in Alto Neuroscience during the fourth quarter valued at $32,453,000. Perceptive Advisors LLC grew its holdings in Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the period. Armistice Capital LLC grew its holdings in Alto Neuroscience by 0.7% during the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after purchasing an additional 12,000 shares during the period. Finally, Vanguard Group Inc. increased its position in Alto Neuroscience by 1.9% in the third quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after buying an additional 20,702 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.